Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

Table 3 Incidence, 5-year survival rate, and index of estimated benefit from lymph node dissection

Lymph node	Type II		Type III		Total
station	Number of patients with dissection	Number of patients with metastasis	Number of patients with dissection	Number of patients with metastasis	Number of patients with dissection	Number of patients with metastasis	5-yr survival rate	IEBLD
1	62	27	21	11	83	38	49.70%	22.8
2	62	14	21	5	83	19	50.70%	11.6
3	62	27	21	14	83	41	53.70%	26.5
4sa	42	1	18	0	60	1	0	0.0
4sb	43	1	19	1	62	2	100%	3.2
4d	39	0	20	0	59	0	NA	0.0
5	25	0	14	1	39	1	0	0.0
6	31	0	21	0	52	0	NA	0.0
7	58	17	21	6	79	23	36.30%	10.6
8	42	4	21	2	63	6	20.80%	2.0
9	32	5	14	2	46	7	42.90%	6.5
10	28	3	12	0	40	3	66.70%	5.0
11p	33	4	19	0	52	4	33.30%	2.6
11d	24	4	11	1	35	5	60%	8.6
12	2	0	1	0	3	0	NA	0.0
16	2	0	0	0	2	0	NA	0.0
LMLN	13	5	3	0	16	5	20%	6.3
MMLN	8	1	0	0	8	1	0	0.0
UMLN	7	1	0	0	7	1	0	0.0

IEBLD: Index of the estimated benefit of lymph-node dissection; Type II: Siewert type II adenocarcinoma of the esophagogastric junction; Type III: Siewert type III adenocarcinoma of the esophagogastric junction; LMLN: Lower mediastinal lymph-node; MMLN: Middle mediastinal lymph-node; UMLN: Upper mediastinal lymph-node.